{'fraction_non_alphanumeric': 0.028142589118198873, 'fraction_numerical': 0.0028142589118198874, 'mean_word_length': 6.731884057971015, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Inhibition of CHOP Chemotherapy‐stimulated Hematological Tumor Growth with Resolvins

Current therapeutic approaches for non‐Hodgkin lymphoma, such as CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone), reduce tumor burden by inducing tumor cell death thereby creating tumor cell debris. This debris can stimulate inflammation in the tumor microenvironment contributing to tumor growth, making cytotoxic therapies a double‐edged sword. A new direction in inflammation research has emerged with the discovery of a novel genus of endogenous anti‐inflammatory and pro‐resolving lipid‐autacoid mediators derived from omega‐3 polyunsaturated fatty acids, including resolvins, which have potent novel inflammation clearing (‘pro‐resolution’) activity without being immunosuppressive. We hypothesize that (1) the failure of endogenous clearance of tumor cell debris can promote hematological cancer progression (2) resolvins represent a novel modality in cancer treatment by enhancing endogenous clearance of tumor debris by macrophage phagocytosis.